An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: A prospective, multicenter study in China

Chinese Medical Journal

Volumn 127, Issue 1, 2014, Pages 59-65

  Li, Tai Sheng ^a   Guo, Fu Ping ^a   Li, Yi Jia ^a   Zhang, Cheng Da ^a   Han, Yang ^a   Lye, Wei ^a   He, Yun ^b   Lu, Hong Zhou ^c   Xie, Jing ^a   Huang, Ai Qiong ^d   Li, Yan Ling ^a   Tang, Xiao Ping ^e   Wang, Hui ^f   Zhang, Tong ^g   Gao, Guiju ^h   Lei, Jun Kang ⁱ   Zhang, Xiao Ying ^a   Wu, Xin Hua ^j   Sun, Yong Tao ^k   Bai, Jin Song ^l   Luo, Ling ^a   Wang, Huan Ling ^a   more..

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Henan Infectious Disease Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d FUJIAN MEDICAL UNIVERSITY   (China)

^e Guangzhou Eighth People's Hospital   (China)

^f SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ Yunnan AIDS Care Center   (China)

^j First People's Hospital of Honghe State   (China)

^k FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^l Third People's Hospital of Kunming   (China)

more..

Author keywords

Acquired immunodeficiency syndrome; Anemia; Antiretroviral therapy; Human immunodeficiency virus; Lipodystrophy; Stavudine; Zidovudine

Indexed keywords

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RESPONSE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STAVUDINE; ZIDOVUDINE;

EID: 84891666268     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132557     Document Type: Article

References (24)

1. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 2007; 8: 465-471.
2. Li T, Dai Y, Kuang J, Jiang J, Han Y, Qiu Z, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 2008; 3: e3918.
3. Liu LF, Wang L, Fu Q, Zhu Z, Xie J, Han Y, et al. Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. Chin Med J 2012; 125: 1931-1935.
4. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Genewa: World Health Organization. (Accessed April 2, 2013 at http://whqlibdoc.who.int/ publications/2010/9789241599764_eng.pdf)
5. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004; 38: 1454-1463.
6. van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One 2012; 7: e42029.
7. Sawawiboon N, Wittawatmongkol O, Phongsamart W, Prasitsuebsai W, Lapphra K, Chokephaibulkit K. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine. Int J Std Aids 2012; 23: 497-501.
8. Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, Sirisanthana V: Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2012; 31: 384-388.
9. Kumarasamy N, Venkatesh KK, Devaleenol B, Saghayam S, Manohar D, Poongulali S, et al. Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting. Int J Infect Dis 2009; 13: e360-e364.
10. Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, et al. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antiviral Ther 2012; 17: 1521-1531.
11. Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 2012; 26: 1755-1763.
12. Thuppal SV, Karthik R, Abraham OC, Wanke CA, Mwamburi M, Terrin N, et al. Cost estimation of first-line antiretroviral therapy with zidovudine/stavudine as the nucleoside backbone in India: a pilot study. J Int Assoc Provid AIDS Care 2013; Epub ahead of print.
13. Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26: 92-97.
14. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40: 219-225.
15. Levine AM, Karim R, Mack W, Gravink DJ, Anastos K, Young M, et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Int Med 2006; 166: 405-410.
16. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192-197.
17. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antiviral Ther 2005; 10: 615-624.
18. Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers H, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1779-1784.
19. Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome (AIDS). Ann Int Med 1988; 109: 718-721.
20. Han SH, Zhou J, Saghayam S, Vanar S, Phanuphak N, Chen YM, et al. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J 2011; 58: 475-484.
21. Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H, Dolmans WM, et al. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J 2013; 32: 39-44.
22. Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr 2012; 59: 274-280.
23. Pujades-Rodríguez M, Dantony E, Pinoges L, Ecochard R, Etard JF, Carrillo-Casas E, et al. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS One 2011; 6: e28112.
24. Isaakidis P, Raguenaud ME, Phe T, Khim SA, Kuoch S, Khem S, et al. Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia. J Acquir Immune Defic Syndr 2008; 49: 48-54.